GATT Technologies B.V. is located in Nijmegen, Netherlands on Toernooiveld 1. GATT Technologies B.V. is rated 3 out of 5 in the category manufacturer in Netherlands. GATT Technologies has developed a proprietary synthetic NHS-POx Technology, as an alternative to NHS-PEG for hemostatic Leadership with very strong features: -very fast hemostasis, also for thin anticoagulated blood -fast and strong adhesion on wet tissue -applicable for all product formulations, allowing for a complete hemostat and sealant portfolio -very tuneable: optimised effectiveness per specific application -very cost effective, scalable production -strong proprietary GATT IP portfolio covering the complete hemostat and sealant product scope Based on this technology, GATT develops surgical hemostats and sealants, with a very fast and strong hemostasis and very high adhesion to wet tissue to address the unmet need of controlling severe bleedings, also for thin anti-coagulated blood. Proof-of-Concepts: GATT has established Proof-of-Concepts confirming the strong characteristics for the following products: GATT-Patch based on several existing collagen, ORC, gelatin patches (actual in-vivo tests proof very strong hemostatic functionality, towards a performance beyond any other known technology and products) GATT-Powder based on several existing hemostatic starch powders GATT-Tape GATT-Spray